The purpose of this study is to get outcomes data for the Adapt Monorail Carotid System used in conjunction with the FilterWire Embolic protection system for treatment of patients that suffer from carotid artery stenosis and that cannot have surgery due to high risk factors.
According to the World Health Organization, 15 million people suffer stroke each year. Of these, 5 million die and another 5 million are permanently disabled. Predominant mechanism responsible for stroke is embolism from proximal rupture of atherosclerotic plaque and thrombus. 25-30% of stroke deaths related to the carotid stenosis. The primary therapy for carotid occlusive disease is the surgical removal of this atherosclerotic plaque from inside the artery. Another treatment option for subjects with significant surgical risk factors has been found: the carotid artery stenting is a non-surgical procedure which unblocks narrowing of the carotid artery lumen by inserting a small metal tube (stent) to keep the plaque against the wall of the artery to improve blood flow.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
100
The Adapt Carotid Stent System is intended to deliver a self-expanding Stent to the extra-cranial carotid arteries via a sheathed percutaneous Monorail delivery system. The Adapt Carotid Stent is a closed cell, self-expanding, rolled nitinol (nickel-titanium alloy) sheet. The stent is thin, flexible and expands to appose the vessel wall. The FilterWire EZ System is a temporary intravascular guide wire filtration system that is placed in the vessel distal to the lesion to be treated. It consists of either a polyurethane filter bag 1.5 cm in length or a Bionate (polycarbonate urethane) filter bag, 1.0 cm in length attached near the distal end of a 0.014" silicone coated stainless steel guide wire by means of a collapsible, self-conforming, Nitinol filter loop wire.
A.Z. Sint Blasius
Dendermonde, East-Flanders, Belgium
Imelda Ziekenhuis
Bonheiden, Belgium
CHU Sart Tilman
Liège, Belgium
Königin Elisabeth Herzberge
30-day rate of major adverse events
30-day rate of major adverse events, defined as the cumulative incidence of any peri-procedural (less or equal to 30 days postprocedure) death, stroke, or Myocardial Infarction
Time frame: 30-day postprocedure
Late ipsilateral stroke
Time frame: 31 through 365 days post procedure
System Technical Success
successful placement and retireval of the FilterWire EZ System, and the successful deployment of the Adapt Carotid Stent sytem in the target carotid artery, with a residual stenosis \< or equal to 30% as determined by the core lab.
Time frame: the procedure time
Device Malfunctions
Define as any failure of the device to meet performance specifications or otherwise perform as intended, as defined by the investigator.
Time frame: from index procedure to 365 days post procedure
Serious device-related and procedure-device related Events
Time frame: from index procedure to 365 days post procedure
Target Lesion Revascularization
any surgical or percutaneous attempt to revascularize the target lesion after the initial or index treatment when the diameter restenosis is either equal to 50% or above with symptoms related to the target lesion or 80% or above without symptoms related to the target lesion.
Time frame: from end of index procedure to 365 days postprocedure
In-stent Restenosis
Time frame: from end of index procedure to 365 days post procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Berlin, Germany
Klinikum Dortmund
Dortmund, Germany
Universitaetsklinikum Heidelberg
Heidelberg, Germany
Park KH
Leipzig, Germany
Klinikum Neuperlach Munich
Munich, Germany
Radiologische Universitätklinik
Tübingen, Germany
Hospital Juan Canalejo
A Coruña, Spain
...and 1 more locations
Major Adverse Events Rate by subgroups
Major Adverse Events Rate by subgroups * symptomatic and asymptomatic status * per center
Time frame: from index procedure to 365 days post procedure